E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic renal cell cancer |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To asses the efficacy of the combination therapy with interferon alfa-2a, vinblastine and bevacizumab in patients with metastatic renal cell carcinoma (RCC) based on progression free survival. |
|
E.2.2 | Secondary objectives of the trial |
- To characterise the safety profile of the combination of bevacizumab with interferon alfa-2a and vinblastine based on the rate of adverse events with CTCAEv3.0 Grade 3, 4 or 5. - To determine the feasibility of the combination of bevacizumab and interferon alfa-2a and vinblastine. - To evaluate the course of blood pressure. - To assess the efficacy of the combination based on overall survival. - To determine the response rate of the combination based on the RECIST criteria. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Willingness to give written informed consent for study participation and for data protection (legal requirement in Germany: ‘Datenschutzrechtliche Einwilligung’).
• Patient must be willing and able to comply with the protocol.
• Patients with metastatic renal cell carcinoma of predominantly clear cell type with at least one measurable lesion according to RECIST criteria.
• Patient was nephrectomized for primary clear cell renal cell carcinoma and postsurgical wound healing is completed..
• Age ≥ 18 years.
• ECOG Performance status ≤ 2.
• The required laboratory values at screening are as follows: Hematology: - Absolute neutrophil count ≥ 1.5 x 109/L - Platelet count > 100 x 109/L. - Hemoglobin > 9 g/dL (may be transfused to maintain or exceed this level). - International Normalized Ratio (INR) ≤ 1.5 x upper limit of normal (ULN); aPTT ≤ 1.5 x ULN. Biochemistry: - Total bilirubin ≤ 1.5 x ULN. - AST, ALT ≤ 2.5 x ULN in patients without liver metastases; < 5 x ULN in patients with liver metastases. - Serum creatinine < 2.0 mg/dL or 177 µmol/L or calculated creatinine clearance ≥ 35 mL/min. Absence of proteinuria at baseline defined as: - Patients with < 1+ proteinuria on dipstick urinalysis. - Patients with ≥ 1+ proteinuria on dipstick urinalysis, who demonstrate < 0.5 g of protein/24 h on 24-h urine collection.
• Life expectancy greater than 3 months.
• Evaluation of tumor-manifestation 4 weeks or less before start of therapy by RECIST criteria.
|
|
E.4 | Principal exclusion criteria |
• Prior treatment with chemotherapy, cytokine or tyrosine kinase inhibitor therapy for RCC (including neo-adjuvant or adjuvant therapy).
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study.
• Serious non-healing wound, ulcer or bone fracture.
• Evidence of bleeding diathesis or coagulopathy.
• Hemapoetic diseases.
• Serious dysfunction of bone marrow.
• History or other evidence of ischemic retinopathy.
• Uncontrolled thyroid disease.
• Uncontrolled hypertension.
• Contraindications of the standard therapy (interferon alfa-2a and vinblastine).
• Seizure(s) not controlled with standard medical therapy.
• Ongoing or recent (within 10 days prior to study treatment start) need for full therapeutic dose of oral or parenteral anticoagulants or chronic daily treatment with aspirin (> 325 mg/day).
• Patients with a medical condition requiring chronic systemic corticosteroids at a dosage of > 10 mg/kg BW methylprednisolone equivalent, excluding inhaled steroids.
• History or presence of other malignancies within the last 5 years (except: cervical carcinoma in situ and basal cell or squamous cell carcinoma of the skin).
• Clinically significant (i.e. active) cardiovascular disease, for example cerebrovascular accidents (≤ 6 months), myocardial infarction (≤ 6 months), unstable angina, New York Heart Association (NYHA) grade ≥ II congestive heart failure, or serious cardiac arrhythmia requiring medication.
• Women, lactating, pregnant or of childbearing potential and fertile men not using a highly effective contraceptive method (Allowed methods of birth control, i.e. with a failure rate of ≤ 1% per year, are implants, injectables, combined oral contraceptives intrauterine devices (only hormone spirals), sexual abstinence or vasectomized partner for up to 6 months after end of treatment). [Women of childbearing potential must have a negative pregnancy test (serum ß-HCG) within 7 days before the first dose of study drug].
• Evidence of current central nervous system (CNS) metastases or spinal cord compression. If clinically indicated, patient must undergo a MRI or CT scan of the brain (with contrast, if possible) within 28 days prior to inclusion.
• Known infection with HBC, HCV, HIV (no testing required)
• History or presence of autoimmune disease (i.e. thyroid autoimmune dysfunction).
• Uncontrolled bacterial infection of any kind.
• Evidence of allergy or hypersensitivity against the used medication and its ingredients.
• Allogenic transplants with a need for immunosuppressive therapy.
• History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications.
• History or presence of a neuromuscular disease.
• Recent (within the 30 days prior to inclusion) treatment with another investigational drug or recent/current participation in another investigational study.
• Patients who have participated in this study before.
• Patients who are underage or patients who are incapable to understand the aim, importance and consequences of the study and to give legal informed consent (according to § 40 Abs. 4, § 41 Abs. 2 and Abs. 3 AMG).
• Patients who are confined by order either of judicial or administrative authorities (according to § 40 Abs. 1 No. 4 AMG).
• Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.
• Patients who possibly are dependent on the sponsor or investigator.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Median progression free survival (PFS). Progression is defined according to RECIST criteria. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 30 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |